Drugs / Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
also known as
DTcP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06857370 | Mar 2025 → Jan 2026 overdue | — | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06857370 ↗ |
| Known as | DTcP | “Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)” NCT06857370 ↗ |
| Modality | Vaccine | “receive three batches of the DTcP trial vaccine” NCT06857370 ↗ |